To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Mediclinic Middle East site visit

Release Date: 12/12/2018 09:00
Code(s): MEI     PDF:  
Wrap Text
Mediclinic Middle East site visit

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")

12 December 2018

Mediclinic Middle East Site Visit

Mediclinic International plc, the international private healthcare services group, will host a site
visit for analysts and institutional investors in Abu Dhabi and Dubai today, 12 December 2018,
and tomorrow, 13 December 2018.

David Hadley, Mediclinic Middle East CEO, will briefly present an overview of the division
focusing on the following key areas:

-   Mediclinic's position as a leading private healthcare provider in the UAE
-   Attractive long-term market fundamentals in the UAE
-   Delivery of superior international standards in patient experience and clinical excellence
-   Expansion opportunities and sustainable long-term growth
-   Future plans across the continuum of care

Guidance for Mediclinic Middle East remains unchanged. The division expects to deliver FY19
revenue growth (adjusted for the adoption of IFRS 15) in the high single-digit percentage range
reflecting the underlying operating performance of the business and additional bed capacity
coming online in the second half of the year. The operating leverage in the underlying business,
offset to some extent by the start-up losses associated with expansion projects, is expected to
deliver a slightly improved EBITDA margin compared to the prior year (adjusted for the adoption
of IFRS 15, FY18: 13.0%). The Group continues to expect ongoing EBITDA margin expansion
to around 20% by FY23 given the ongoing improvements and expansion opportunities across
the region.

No new material information will be provided during the event. Presentation material will be
made available online shortly after 7am GMT on https://ir.mediclinic.com/results-
centre/presentations-and-investor-days.

About Mediclinic International plc
Mediclinic is an international private healthcare services group, established in South Africa in
1983, with current operating divisions in Southern Africa (South Africa and Namibia),
Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of
patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-
based private healthcare group.

Mediclinic comprises 76 hospitals and 30 clinics. Hirslanden operates 18 private hospitals and
4 clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates
48 hospitals and 4 day clinics throughout South Africa and 3 hospitals in Namibia with more
than 8 100 inpatient beds in total; and Mediclinic Middle East operates 7 hospitals and 22 clinics
with more than 900 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with
secondary listings on the JSE in South Africa and the NSX in Namibia.

The divisions' contributions to Group revenue for the financial year ended 31 March 2018 were
47% by Hirslanden, 31% by Mediclinic Southern Africa and 22% by Mediclinic Middle East.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with
secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 12/12/2018 09:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story